99mTc-FAPI-positive Gastrointestinal Tumor
Conditions
Brief summary
The purpose of this study is to compare the similarities and differences of 99mTc-FAPI quantitative SPECT/CT and 68Ga-FAPI PET/CT in the diagnosis and staging of gastrointestinal tumors, and clinical diagnosis and economic value of 99mTc-FAPI quantitative SPECT/CT for the gastrointestinal tumors.
Detailed description
5 healthy volunteers with whole body 99mTc-FAPI quantitative SPECT/CT scans at 1, 2, 4, 6 and 24 hours after tracer injection (mean dose, 20.0 ± 2.0 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 2, 4, 6 and 24 hours after the injection, for time-activity curve calculations. The estimated radiation doses will be calculated by using OLINDA/EXM software. Forty patients with confirmed or suspected gastrointestinal tumors, whole body 99mTc-FAPI quantitative SPECT/CT scans will be performed on the first day, and whole body 68Ga-FAPI PET/CT scans will be performed on the next day.According to the scans results of the two agents, with SUVmax and SUVmean as the analysis indicators, the number and uptake difference of primary tumor and metastatic lesions will be compared and analyzed.
Interventions
DIAGNOSTIC_TEST99mTc-FAPI
inject the tracer to subjects and perform SPECT/CT scans
Sponsors
Xijing Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* patients with gastrointestinal tumors: diagnosed by pathological needle biopsy
Exclusion criteria
* refuse or cannot endure surgery pregnant women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUV of primary and metastases lesions | 2 hours after injection | The standardized uptake values (SUV) in deferent organs and lesions |
Contacts
Primary ContactJing Wang, M.D, Ph.D
Outcome results
None listed